0000000000246838

AUTHOR

Brigette B.y. Ma

showing 3 related works from this author

MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

2018

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyAtezolizumab030220 oncology & carcinogenesisInternal medicinemedicineErlotinibLong term safetybusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC

2017

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyAtezolizumab030220 oncology & carcinogenesisInternal medicineMedicineBiomarker (medicine)Erlotinibbusinessmedicine.drugJournal of Thoracic Oncology
researchProduct